SCHEDULE 13G/A: Octagon Capital Advisors and Affiliates Report Significant Stake in Dianthus Therapeutics
Beneficial Ownership Report
Octagon Capital Advisors LP, along with its affiliated funds and managing member Ting Jia, has reported a collective beneficial ownership of 7.1% in Dianthus Therapeutics, Inc. common stock as of December 31, 2024.
Summary
- Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Octagon Private Opportunities Fund II LP, and Ting Jia (collectively, the "Reporting Persons") have jointly filed an Amendment No. 1 to Schedule 13G.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 2,110,167 shares of Dianthus Therapeutics, Inc. common stock.
- This aggregate amount represents 7.1% of the Issuer's common stock outstanding.
- The percentage is calculated based on 29,596,965 common shares outstanding as of November 5, 2024, as reported by Dianthus Therapeutics, Inc. in its Form 10-Q filed on November 7, 2024.
- Octagon Capital Advisors LP serves as the investment manager for Octagon Investments Master Fund LP and Octagon Private Opportunities Fund II LP.
- Ting Jia is the managing member of Octagon Capital Advisors LP and is deemed to beneficially own the shares held by the funds.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership, providing factual information without expressing a specific sentiment regarding the company's performance or outlook.
Future Outlook
The document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of institutional ownership in a publicly traded company, Dianthus Therapeutics, Inc., which operates in the biotechnology or pharmaceutical sector. Such disclosures provide transparency on significant investor positions but do not offer insights into broader industry trends or competitive dynamics.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership stakes, which can influence investor perception and market liquidity.
Key Dates
| Date | Description |
|---|---|
| November 5, 2024 | Date of 29,596,965 Common Shares outstanding, as reported in the Issuer's Form 10-Q. |
| December 31, 2024 | Date of event which required the filing of this statement (beneficial ownership threshold crossed). |
| February 5, 2025 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
Dianthus Therapeutics, Octagon Capital Advisors, SEC filing, Schedule 13G, beneficial ownership, institutional ownership, common stock, investment fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.